In The Media

The Satya Vadlamani Story illuminates the remarkable trajectory of an extraordinary entrepreneur whose indomitable spirit and unwavering determination propelled her from humble beginnings to the zenith of success. Dr. Satya Vadlamani’s narrative transcends the conventional bounds of entrepreneurship, offering readers an intimate glimpse into the trials, triumphs, and transformative moments that shaped her illustrious career.

Oral insulin, which refers to insulin that is taken by mouth rather than being injected, has been a subject of research and development for many years. We at MKPPL are working on a sub lingual formulation. Our product so far is stable and is based on human insulin and is long lasting. While there have been challenges in developing an effective oral insulin formulation, if successfully developed, oral insulin could offer several benefits.

Anaemia is a common complication among patients with chronic kidney disease (CKD). CKD refers to the gradual loss of kidney function over time, and it can lead to various health issues, including anemia. Iron levels are frequently low in CKD patients, and providing supplemental iron can help improve red blood cell production. This is where MKPPL iron fortification through MK-VitFe gets into place. The product being Transdermal helps in bringing up the lowered haemoglobin levels to normal levels without the need for iron injections.

MKVit-Fe with Ease of Doing Business driving towards an Anaemia Mukt Bharat through DIISHA

Dr. Satya Vadlamani, Chairperson and Managing Director, Murli Krishna Pharma Private Ltd addressing on Transdermal Oil - Interventions for Addressing Anemia Among Children and Adolescents – A Murli Krishna Pharma Case Study at the at the 15th Annual Pharma Leaders Power Brand Awards 2022.

From establishing and leading Murli Krishna Pharma to change the Pharma landscape of India, Dr. Vadlamani has touched and transformed lives with her sheer passion, grit and determination. From being a Regulatory Compliant prefinished formulation intermediates facility in 2004 to becoming a finished dosage firm based on the FTF formulation, the growth trajectory of MKPPL, under the leadership of Dr. Vadlamani has been quite an inspiring one. She outlines MKPPL’s journey hosting to innovations, product pipeline & plans and concludes with an inspiring advice for youngsters.

Dr. Satya Vadlamani, Founder, Chairperson & Managing Director of Murli Krishna Pharma Pvt. Ltd. addressing NexBrands Brand Vision Summit 2022.

Dr. Satya Vadlamani, Founder, Chairperson & Managing Director of Murli Krishna Pharma Pvt. Ltd. addressing on Healthcare Reforms at the 12th Annual India Leadership Conclave & Indian Affairs Power Brand Awards 2021.

Dr.Satya Vadlamani,Chairperson & Managing Director, Murlikrishna Pharma Pvt.Ltd. voted as Indian Affairs Inspirational Women Business Reformer of the Year 2021 at the iconic & prestigious 12th Annual India Leadership Conclave & Indian Affairs Business Leadership Awards 2021.

Dr Satya Vadlamani's contribution towards the building of the nation is immense, as apparent in the past more than two decades, which she has dedicated to bringing smiles to innumerable faces.

Having established Murli Krishna Pharma Pvt. Ltd. with Dr Vijay Shastri and a group of 4 Directors, she commissioned the manufacturing plant in 2005, and within two years obtained the first European Union (EU) approval for a single molecule.

Her experience of more than two decades helps her innovate and create out-of-the-box ideas and products in her current organization.